Immunovant, Inc. (IMVT)
$40.58-$3.24 (-7.39%) Today
Tiago Girao - Officer
Jay S. Stout - OfficerImmunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 24 | 116,704 | $4.50M |
| Option exercise | 14 | 252,024 | |
| Derivative transaction | 1 | 86,629 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
70 Form 4 filings on record, the earliest from Oct 11, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Atul Pande - Director | Option exercise | Common Stock | 1,500 | $8.43 | $13K | |
| Atul Pande - Director | Open-market sale | Common Stock | 1,500 | $43.27 | $65K | |
| Atul Pande - Director | Option exercise | Stock Option (right to buy) | 1,500 | $0.00 | - | |
| Melanie Gloria - Officer | Open-market sale | Common Stock | 3,056 | $44.16 | $135K | |
| Atul Pande - Director | Option exercise | Common Stock | 1,500 | $8.43 | $13K | |
| Atul Pande - Director | Open-market sale | Common Stock | 1,500 | $39.80 | $60K | |
| Atul Pande - Director | Option exercise | Stock Option (right to buy) | 1,500 | $0.00 | - | |
| Tiago Girao - Officer | Open-market sale | Common Stock | 6,798 | $38.69 | $263K | |
| Jay S. Stout - Officer | Open-market sale | Common Stock | 2,857 | $38.69 | $111K | |
| Melanie Gloria - Officer | Open-market sale | Common Stock | 1,930 | $39.53 | $76K | |
| Melanie Gloria - Officer | Open-market sale | Common Stock | 106 | $39.99 | $4K | |
| Tuyl Christopher van - Officer | Open-market sale | Common Stock | 1,143 | $39.53 | $45K | |
| Tuyl Christopher van - Officer | Open-market sale | Common Stock | 63 | $39.99 | $3K | |
| Jay S. Stout - Officer | Open-market sale | Common Stock | 1,906 | $39.53 | $75K | |
| Jay S. Stout - Officer | Open-market sale | Common Stock | 105 | $39.99 | $4K | |
| Jay S. Stout - Officer | Open-market sale | Common Stock | 1,399 | $39.53 | $55K | |
| Jay S. Stout - Officer | Open-market sale | Common Stock | 77 | $39.99 | $3K | |
| Eric Venker - Officer | Option exercise | Common Stock | 92,188 | $14.46 | $1.33M | |
| Eric Venker - Officer | Derivative | Common Stock | 86,629 | $38.14 | $3.30M | |
| Eric Venker - Officer | Open-market sale | Common Stock | 3,092 | $38.48 | $119K | |
| Eric Venker - Officer | Option exercise | Capped Value Appreciation Rights | 92,188 | $0.00 | - | |
| Melanie Gloria - Officer | Open-market sale | Common Stock | 14,748 | $38.18 | $563K | |
| Melanie Gloria - Officer | Open-market sale | Common Stock | 2,966 | $38.95 | $116K | |
| Jay S. Stout - Officer | Open-market sale | Common Stock | 6,723 | $38.94 | $262K | |
| Jay S. Stout - Officer | Open-market sale | Common Stock | 33,277 | $38.18 | $1.27M | |
| Tuyl Christopher van - Officer | Option exercise | Common Stock | 17,824 | $15.20 | $271K | |
| Tuyl Christopher van - Officer | Open-market sale | Common Stock | 14,982 | $38.19 | $572K | |
| Tuyl Christopher van - Officer | Open-market sale | Common Stock | 2,842 | $38.96 | $111K | |
| Tuyl Christopher van - Officer | Option exercise | Stock Option (right to buy) | 17,824 | $0.00 | - | |
| Tiago Girao - Officer | Option exercise | Common Stock | 10,000 | $15.90 | $159K | |
| Tiago Girao - Officer | Open-market sale | Common Stock | 10,000 | $38.46 | $385K | |
| Tiago Girao - Officer | Option exercise | Stock Option (right to buy) | 10,000 | $0.00 | - | |
| Atul Pande - Director | Option exercise | Common Stock | 1,500 | $8.43 | $13K | |
| Atul Pande - Director | Open-market sale | Common Stock | 1,500 | $38.01 | $57K | |
| Atul Pande - Director | Option exercise | Stock Option (right to buy) | 1,500 | $0.00 | - | |
| Tuyl Christopher van - Officer | Open-market sale | Common Stock | 2,634 | $35.39 | $93K | |
| Atul Pande - Director | Open-market sale | Common Stock | 1,500 | $34.02 | $51K | |
| Atul Pande - Director | Option exercise | Stock Option (right to buy) | 1,500 | $0.00 | - | |
| Atul Pande - Director | Option exercise | Common Stock | 1,500 | $8.43 | $13K | |
| Andrew J. Fromkin - Director | Option exercise | Common Stock | 31,668 | $4.99 | $158K | |
| Andrew J. Fromkin - Director | Option exercise | Common Stock | 71,492 | $7.94 | $568K | |
| Andrew J. Fromkin - Director | Option exercise | Common Stock | 77,181 | $8.43 | $651K | |
| Andrew J. Fromkin - Director | Option exercise | Common Stock | 16,260 | $14.70 | $239K | |
| Andrew J. Fromkin - Director | Open-market sale | Common Stock | 11,483 | $32.64 | $375K | |
| Andrew J. Fromkin - Director | Open-market sale | Common Stock | 210,468 | $33.56 | $7.06M | |
| Andrew J. Fromkin - Director | Option exercise | Stock Option (right to buy) | 31,668 | $0.00 | - | |
| Andrew J. Fromkin - Director | Option exercise | Stock Option (right to buy) | 71,492 | $0.00 | - | |
| Andrew J. Fromkin - Director | Option exercise | Stock Option (right to buy) | 77,181 | $0.00 | - | |
| Andrew J. Fromkin - Director | Option exercise | Stock Option (right to buy) | 16,260 | $0.00 | - | |
| Melanie Gloria - Officer | Open-market sale | Common Stock | 249 | $30.41 | $8K | |
| Melanie Gloria - Officer | Open-market sale | Common Stock | 1,168 | $32.15 | $38K | |
| Melanie Gloria - Officer | Open-market sale | Common Stock | 1,698 | $32.95 | $56K | |
| Atul Pande - Director | Option exercise | Common Stock | 6,000 | $8.43 | $51K | |
| Atul Pande - Director | Open-market sale | Common Stock | 6,000 | $32.00 | $192K | |
| Atul Pande - Director | Option exercise | Stock Option (right to buy) | 6,000 | $0.00 | - | |
| Robert Graham Susman - Director | Open-market sale | Common Stock | 2,502 | $27.17 | $68K | |
| Tiago Girao - Officer | Open-market sale | Common Stock | 25,760 | $29.62 | $763K | |
| Jay S. Stout - Officer | Open-market sale | Common Stock | 2,754 | $29.62 | $82K | |
| Tuyl Christopher van - Officer | Open-market sale | Common Stock | 5,165 | $24.83 | $128K | |
| Melanie Gloria - Officer | Open-market sale | Common Stock | 8,722 | $24.83 | $217K | |
| Jay S. Stout - Officer | Open-market sale | Common Stock | 8,614 | $24.83 | $214K | |
| Jay S. Stout - Officer | Open-market sale | Common Stock | 1,518 | $24.83 | $38K | |
| Frank Torti - Director | Grant or award | Common Stock | 174,189 | $0.00 | - | |
| Frank Torti - Director | Grant or award | Stock Option (right to buy) | 88,325 | $0.00 | - | |
| Andrew J. Fromkin - Director | Grant or award | Common Stock | 13,880 | $0.00 | - | |
| Andrew J. Fromkin - Director | Grant or award | Stock Option (right to buy) | 7,061 | $0.00 | - | |
| Douglas J. Hughes - Director | Grant or award | Common Stock | 13,880 | $0.00 | - | |
| Douglas J. Hughes - Director | Grant or award | Stock Option (right to buy) | 7,061 | $0.00 | - | |
| Atul Pande - Director | Grant or award | Common Stock | 13,880 | $0.00 | - | |
| Atul Pande - Director | Grant or award | Stock Option (right to buy) | 7,061 | $0.00 | - | |
| Jake Bauer - Director | Grant or award | Common Stock | 13,880 | $0.00 | - | |
| Jake Bauer - Director | Grant or award | Stock Option (right to buy) | 7,061 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Immunovant, Inc. (IMVT) had 16 insider filings in the last 90 days, with the most recent on 2026-08-28. The full record for IMVT runs to 70 Form 4 filings, the earliest from 2024-10-11. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of IMVT were filed in the last 90 days.
24 insider sales of IMVT were filed in the last 90 days, totaling $4.50M.
This page tracks IMVT Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add IMVT to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
